A decades-old lab-made brain compound used off-label as a cognitive enhancer. Its clearest signal is modest improvement in thinking after head injury; use for blood-flow-related memory decline rests on older, weaker studies. It shows no proven benefit in already-healthy people or for brain-aging. Short-term safety looks mild; long-term value and safety remain unproven. (Full Review)

Protocol

Standard Dose

800–2,400 mg/day

Racemic oxiracetam orally, ~800 mg twice daily; off-label cognitive-enhancement range

Timing

Morning & early afternoon

Mildly stimulating; late-day dosing risks insomnia

Dose Splitting

Split into 2–3 doses

~6-hour half-life; splitting maintains more even blood levels through the day

Time to effect

Cognitive Benefit

Weeks to a few months

Any cognitive benefit in impaired populations developed over continued dosing

Acute Effect

~1 hour

Rapid absorption; acute effects, if any, felt within about an hour of a dose

Benefits

Medium: Cognitive recovery after traumatic brain injury

Low: Cognitive improvement in vascular and post-stroke cognitive impairment; symptomatic support in dementia and age-related cognitive decline

Speculative: Enhanced cognition in healthy adults; neuroprotection and brain resilience for longevity

Contraindications

Pregnant or breastfeeding individuals

Children and adolescents outside a clinical trial

Significant kidney impairment (eGFR below 30 mL/min/1.73m²)

Seizure disorder or uncontrolled anxiety

Key Interactions

Cholinergic drugs and supplements (donepezil, rivastigmine, galantamine, alpha-GPC, CDP-choline/citicoline)

Central nervous system stimulants (caffeine, methylphenidate, amphetamine salts, other excitatory nootropics)

Other racetams and phenibut-type compounds (piracetam, aniracetam, phenylpiracetam, phenibut)

Risk & Side Effects

Medium: Central nervous system stimulation (insomnia, agitation, headache)

Low: Gastrointestinal upset; choline depletion symptoms

Speculative: Unknown long-term and longevity safety; contaminant and mislabeling exposure from unregulated products

Monitoring

Marker	Target	Why
eGFR (kidney filtration)	> 90 mL/min/1.73m²	Drug is cleared unchanged by kidneys; low function raises exposure
Serum creatinine	0.6–1.0 mg/dL (lower-normal)	Complements eGFR in gauging renal clearance
Blood pressure	< 120/80 mmHg	Screens for cardiovascular status before a stimulating compound
Baseline cognitive test score	Individual baseline (e.g., MoCA ≥ 26/30)	Reference point to detect real change and gauge deficit

Cadence: Baseline before starting; recheck kidney function periodically with extended use; repeat cognitive testing at 4–8 weeks, then every 3–6 months if continued

Qualitative Assessment

Memory and recall in daily tasks
Mental clarity and focus during demanding work
Verbal fluency and word-finding ease
Sleep quality (watching for stimulation-related disruption)
Energy and mood, including any nervousness or agitation

Oxiracetam for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment